Stock Market Reviews

Read and share opinions on KPRX (Kiora Pharmaceuticals, Inc.) stock. Join MyTopStock.com to discover reviews, insights, and discussions from investors about this company's performance in the stock mar

Latest News

• Kiora Pharmaceuticals Reports Third Quarter 2025 Results; Company Advances Pipeline with Two Actively Enrolling Phase 2 Clinical Trials for Retinal Diseases
  Nov 7, 2025
• Kiora Pharmaceuticals Joins RARE-X Vision Consortium Promoting Collaboration and Development of New Treatments for Rare Ocular Disorders
  Oct 30, 2025
• Kiora Pharmaceuticals to Participate in the 2025 Maxim Growth Summit and Eyecelerator @ AAO 2025
  Oct 15, 2025
• Kiora Pharmaceuticals to Webcast On-Demand Presentation at The H.C. Wainwright 27th Annual Global Investment Conference
  Sep 4, 2025
• Kiora Pharmaceuticals Reports Second Quarter 2025 Results; Company Advances Pipeline with Two Active Phase 2 Clinical Trials for Retinal Diseases
  Aug 8, 2025
• Kiora Pharmaceuticals to Showcase Its Retinal Disease Therapeutic Pipeline at The H.C. Wainwright 5th Annual Ophthalmology Virtual Conference
  Aug 7, 2025
• Kiora Pharmaceuticals Granted U.S. Patent Expanding Protection for KIO-104 in the Treatment of Ocular Disease
  Jul 22, 2025
• Kiora Pharmaceuticals (KPRX) Upgraded to Strong Buy: Here's What You Should Know
  Jul 16, 2025
• Kiora Pharmaceuticals and Senju Pharmaceutical Partner on KIO-301 for the Treatment of Retinal Diseases in Asia
  Jun 3, 2025
• Kiora Pharmaceuticals Reports First Quarter Results; Initiating Two Phase 2 Trials for Treatment of Retinal Diseases; Cash and Short-term Investments Expected to Fund Operations into Late 2027
  May 9, 2025
• Kiora Pharmaceuticals Presents In Vivo Preclinical Data at ARVO 2025 Demonstrating the Potential of KIO-104 to Treat Proliferative Vitreoretinopathy
  May 5, 2025
• Kiora Pharmaceuticals to Present at The 24th Annual Needham Virtual Healthcare Conference
  Apr 4, 2025
• Kiora Pharmaceuticals Reports 2024 Results; Retinal Disease Drug Development Pipeline Continues to Advance; Cash and Short-Term Investments Expected to Fund Operations into 2027
  Mar 25, 2025
• Kiora Pharmaceuticals to Present Preclinical Data on KIO-104 for the Treatment of Proliferative Vitreoretinopathy at the ARVO 2025 Annual Meeting
  Mar 12, 2025
• Kiora Pharmaceuticals Secures U.S. Composition-of-Matter Patent Expanding Protection of Its Anti-Inflammatory Compound KIO-104
  Feb 13, 2025
• Kiora Receives Approval to Initiate KLARITY, a Phase 2 Clinical Trial of KIO-104 for the Treatment of Retinal Macular Edema
  Feb 11, 2025